49 results on '"Melquist, Stacey"'
Search Results
2. RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts
3. Abstract 17091: ARO-APOC3, an Investigational RNAi Therapeutic, Silences APOC3 and Reduces Atherosclerosis-Associated Lipoproteins in Patients With Mixed Dyslipidemia: MUIR Study Results
4. Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia
5. Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)
6. Common dysregulation network in the human prefrontal cortex underlies two neurodegenerative diseases.
7. RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia
8. Plozasiran (ARO-APOC3), decreases APOC3 and triglycerides (TG) in patients with mixed dyslipidemia: MUIR final results
9. Plozasiran (ARO-APOC3), an investigational RNAI therapeutic, demonstrates profound and durable reductions in APOC-3 and triglycerides (TG) in patients with severe hypertriglyceridemia (SHTG), SHASTA-2 final results
10. Abstract 15751: Pharmacodynamic Effect of ARO-ANG3, an Investigational RNA Interference Targeting Hepatic Angiopoietin-like Protein 3, in Patients With Hypercholesterolemia
11. Abstract 12594: Pharmacodynamic Effect of ARO-APOC3, an Investigational Hepatocyte-targeted RNA Interference Therapeutic Targeting Apolipoprotein C3, in Patients With Hypertriglyceridemia and Multifactorial Chylomicronemia
12. RNA interference targeting hepatic angiopoietin-like protein 3 results in prolonged reductions in serum triglyceride and non-HDL-cholesterol concentrations: first human results with ARO-ANG3
13. Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease
14. †Plozasiran (ARO-APOC3), an Investigational RNAi, Demonstrates Deep and Durable TG Reductions in Patients With SHTG, SHASTA-2 Final Results
15. †Plozasiran (ARO-APOC3), an Investigational RNAi, Demonstrates Robust and Durable TG Reductions in Patients with Mixed Dyslipidemia, MUIR Final Results
16. Evidence for an association between KIBRA and late-onset Alzheimer's disease
17. Abstract 10357: ARO-APOC3, an Investigational RNAi Therapeutic, Shows Similar Efficacy and Safety in Genetically Confirmed FCS and Non-FCS Participants with Severe Hypertriglyceridemia
18. Identification of a novel risk locus for progressive supranuclear palsy by a pooled genomewide scan of 500,288 single-nucleotide polymorphisms
19. Identification of the genetic basis for complex disorders by use of pooling-based genomewide single-nucleotide-polymorphism association studies
20. An internal rearrangement in an Arabidopsis inverted repeat locus impairs DNA methylation triggered by the locus
21. Reduced Expression of Angiopoietin-Like Protein 3 via RNA Interference with ARO-ANG3 Produces Prolonged Reductions in LDL-C and Triglycerides in Dyslipidemic Patients
22. First Results of RNA Interference Against Apolipoprotein C3 as a Treatment for Chylomicronemia
23. LRRK2 mutations are not common in Alzheimer's disease
24. Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration
25. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
26. A family with tau-negative frontotemporal dementia and neuronal intranuclear inclusions linked to chromosome 17
27. High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy
28. APOE ε4 lowers age at onset and is a high risk factor for Alzheimer's disease; A case control study from central Norway
29. Abstract 36: Factor XII RNAi-based Therapeutic as a Prophylactic Anti-thrombotic Therapy
30. RNAI-BASED THERAPEUTIC TARGETING FACTOR 12 AS A PROPHYLACTIC TREATMENT FOR THROMBOEMBOLISM
31. Transcription from an upstream promoter controls methylation signaling from an inverted repeat of endogenous genes in Arabidopsis
32. Discovery of 6-(Fluoro-18F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([18F]-MK-6240): A Positron Emission Tomography (PET) Imaging Agent for Quantification of Neurofibrillary Tangles (NFTs)
33. Abstract 428: Lipoprotein(a) Targeting With RNAi Delivery Platforms in Transgenic Mice and Cynomolgus Monkeys
34. Targeting Factor 12 (F12) with a Novel RNAi Delivery Platform As a Prophylactic Treatment for Hereditary Angioedema (HAE)
35. Discovery of 6-(Fluoro-18 F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([18F]-MK-6240): A Positron Emission Tomography (PET) Imaging Agent for Quantification of Neurofibrillary Tangles (NFTs).
36. P1-033: Effect of Tween-20 on levels of core biomarkers measured in human cerebrospinal fluid from patients with Alzheimer's disease or healthy control individuals
37. P3-095: Changes in core biomarkers in cerebrospinal fluid and cognitive ability in patients with Alzheimer's disease: A two-year longitudinal study
38. GAB2 Alleles Modify Alzheimer's Risk in APOE ɛ4 Carriers
39. Risk-reducing effect of education in Alzheimer's disease
40. APOE ε4 lowers age at onset and is a high risk factor for Alzheimer's disease; A case control study from central Norway
41. Analysis of UBQLN1 Variants in a Polish Alzheimer’s Disease Patient: Control Series
42. S2–02–06: The tauopathies: From genetics to animal models
43. P3-163: Identification of a novel risk gene for progressive supranuclear palsy by a genome-wide scan of 500,288 SNPs
44. P4-097 Determination of population structure in the mayo Alzheimer's disease patient registry
45. Arabidopsis PAI gene arrangements, cytosine methylation and expression
46. Changes in core biomarkers in cerebrospinal fluid and cognitive ability in patients with Alzheimer's disease: A two-year longitudinal study
47. Effect of Tween-20 on levels of core biomarkers measured in human cerebrospinal fluid from patients with Alzheimer's disease or healthy control individuals
48. APOE epsilon 4 lowers age at onset and is a high risk factor for Alzheimer's disease; a case control study from central Norway.
49. Whole genome association analysis shows that ACE is a risk factor for Alzheimer's disease and fails to replicate most candidates from Meta-analysis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.